AR076570A1 - Moleculas de union humanas capaces de neutralizar el virus de la influenza h3n2 y usos de las mismas - Google Patents

Moleculas de union humanas capaces de neutralizar el virus de la influenza h3n2 y usos de las mismas

Info

Publication number
AR076570A1
AR076570A1 ARP100101631A ARP100101631A AR076570A1 AR 076570 A1 AR076570 A1 AR 076570A1 AR P100101631 A ARP100101631 A AR P100101631A AR P100101631 A ARP100101631 A AR P100101631A AR 076570 A1 AR076570 A1 AR 076570A1
Authority
AR
Argentina
Prior art keywords
influenza virus
antibodies
neutralizing
same
influenza
Prior art date
Application number
ARP100101631A
Other languages
English (en)
Inventor
Mark Throsby
Robert H E Friesen
Theodorus H J Kwaks
Mandy A C Jongeneelen
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of AR076570A1 publication Critical patent/AR076570A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus

Abstract

La presente solicitud se relaciona con moléculas de union, tales como anticuerpos monoclonales humanos que se unen a distintos virus de la influenza que comprenden HA del subtipo H3, tales como H3N2, y que tienen una amplia actividad neutralizante contra dicho virus de la influenza. Se proveen moléculas de ácido nucleico que codifican los anticuerpos, sus secuencias y composiciones que los comprenden y métodos para identificarlos y producirlos. Los anticuerpos se pueden usar en el diagnostico, profilaxis y/o tratamiento de una infeccion por el virus de la influenza H3N2. En una realizacion preferida, los anticuerpos proveen proteccion cruzada contra distintos subtipos, de modo tal que se pueden prevenir y/o tratar infecciones por subtipos de influenza basados en H3, H7, y/o H10.
ARP100101631A 2009-05-11 2010-05-11 Moleculas de union humanas capaces de neutralizar el virus de la influenza h3n2 y usos de las mismas AR076570A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21589009P 2009-05-11 2009-05-11
EP09159947 2009-05-11
EP10151155 2010-01-20

Publications (1)

Publication Number Publication Date
AR076570A1 true AR076570A1 (es) 2011-06-22

Family

ID=42271865

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101631A AR076570A1 (es) 2009-05-11 2010-05-11 Moleculas de union humanas capaces de neutralizar el virus de la influenza h3n2 y usos de las mismas

Country Status (19)

Country Link
US (2) US8470327B2 (es)
EP (1) EP2430046B1 (es)
JP (2) JP5813629B2 (es)
KR (1) KR101790354B1 (es)
CN (2) CN102448986B (es)
AR (1) AR076570A1 (es)
AU (1) AU2010247530B2 (es)
BR (1) BRPI1012749B1 (es)
CA (1) CA2761648C (es)
CU (1) CU23938B1 (es)
EA (1) EA029939B8 (es)
ES (1) ES2934102T3 (es)
IL (1) IL216222A (es)
MX (1) MX2011011331A (es)
MY (1) MY183517A (es)
NZ (1) NZ596032A (es)
SG (1) SG176003A1 (es)
TW (1) TWI589300B (es)
WO (1) WO2010130636A1 (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009618A2 (en) 2002-07-18 2004-01-29 Crucell Holland B.V. Recombinant production of mixtures of antibodies
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
EP1639009B1 (en) 2003-05-30 2013-02-27 Merus B.V. Fab library for the preparation of a mixture of antibodies
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
US8192927B2 (en) 2006-09-07 2012-06-05 Crucell Holland B.V. Human bind molecules capable of neutralizing influenza virus h5n1 and uses thereof
AU2008338691B2 (en) 2007-12-06 2015-01-22 Burnham Institute For Medical Research Antibodies against influenza virus and methods of use thereof
US9051359B2 (en) 2009-03-30 2015-06-09 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
CA2761648C (en) 2009-05-11 2019-03-12 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
CA2800182A1 (en) 2009-05-26 2010-12-02 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
KR20120132506A (ko) 2010-02-18 2012-12-05 마운트 시나이 스쿨 오브 메디슨 인플루엔자 바이러스 질환의 예방 및 치료에 사용되는 백신
WO2011123495A1 (en) 2010-03-30 2011-10-06 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
WO2012009790A1 (en) 2010-07-22 2012-01-26 Schrader John W Cross-protective pathogen protection, methods and compositions thereof
SG187251A1 (en) 2010-08-03 2013-02-28 Univ Washington Ct Commerciali Polypeptides for treating and/or limiting influenza infection
EP2699688A1 (en) * 2011-04-20 2014-02-26 The Trustees Of The University Of Pennsylvania Regimens and compositions for aav-mediated passive immunization of airborne pathogens
CN103906763B (zh) 2011-07-14 2016-10-12 克鲁塞尔荷兰公司 能够中和系统发育群1和系统发育群2的a型流感病毒以及b型流感病毒的人结合分子
US10131695B2 (en) 2011-09-20 2018-11-20 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
WO2013059524A2 (en) 2011-10-18 2013-04-25 Emory University Antibodies directed against influenza
AU2012343981B2 (en) 2011-11-28 2017-09-07 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
KR20130059721A (ko) * 2011-11-29 2013-06-07 (주)셀트리온 인간 ｂ 세포에서 생산된 인플루엔자 ａ 바이러스 중화 활성을 가지는 결합 분자
WO2013081463A2 (en) 2011-12-02 2013-06-06 Aimm Therapeutics B.V. Influenza a virus specific antibodies
JP6371222B2 (ja) 2011-12-05 2018-08-08 トレリス バイオサイエンス リミテッド ライアビリティー カンパニー インフルエンザの受動免疫用抗体
JP6328061B2 (ja) 2012-03-08 2018-05-23 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Ｂ型インフルエンザウイルスに結合して中和することができるヒト結合分子およびその使用
WO2013138259A2 (en) 2012-03-13 2013-09-19 University Of Washington Through Its Center For Commercialization Polypeptides for treating and/or limiting influenza infection
LT2838918T (lt) 2012-04-20 2019-09-10 Merus N.V. Būdai ir priemonės heterodimerinių ig-tipo molekulių gamybai
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
EP2712626A1 (en) 2012-09-28 2014-04-02 Fabentech Passive immunisation against influenza, in particular H5N1
EA201590731A1 (ru) 2012-11-13 2015-11-30 Дженентек, Инк. Антитела к гемагглютинину и способы применения
KR20150104117A (ko) 2012-12-18 2015-09-14 이칸 스쿨 오브 메디슨 엣 마운트 시나이 인플루엔자 바이러스 백신 및 그의 용도
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
US9649375B2 (en) 2013-03-14 2017-05-16 The Administrators Of The Tulane Educational Fund Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith
US9624272B2 (en) 2013-03-14 2017-04-18 University Of Washington Through Its Center For Commercialization Polypeptides for treating and/or limiting influenza infection
MX2015012397A (es) 2013-03-14 2016-07-26 Contrafect Corp Composiciones y metodos basados en anticuerpos neutralizados suministrados intranasalmente para eficacia terapeutica aumentada.
KR20140118682A (ko) * 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
KR101511619B1 (ko) * 2013-04-30 2015-04-13 한국생명공학연구원 개 인플루엔자 바이러스 h3n2의 ha1 단백질을 항원으로 포함하는 개 인플루엔자 바이러스 h3n2에 특이적인 혈청 진단용 키트
EP3004142B1 (en) 2013-05-30 2020-09-30 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
RU2682049C2 (ru) * 2014-01-27 2019-03-14 Дженентек, Инк. Лечение вируса гриппа а h7n9
CN106795216B (zh) 2014-02-04 2021-04-20 抗非特公司 可用于被动流感免疫的抗体及其组合物、组合和使用方法
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
CN105992772A (zh) 2014-02-10 2016-10-05 Igm生命科学股份有限公司 IgA多特异性结合分子
WO2015143339A2 (en) 2014-03-21 2015-09-24 University Of Washington Enhanced influenza hemagglutinin binders
KR101628331B1 (ko) * 2014-03-28 2016-06-08 주식회사 녹십자엠에스 인플루엔자 a 바이러스 특이적 단클론 항체 및 이를 이용한 인플루엔자 감염 치료 및 진단 방법
SG11201609207SA (en) 2014-05-13 2016-12-29 Univ Pennsylvania Compositions comprising aav expressing dual antibody constructs and uses thereof
EA038400B1 (ru) 2014-07-10 2021-08-23 Янссен Вэксинс Энд Превеншн Б.В. Полипептид стеблевого домена гемагглютинина вируса гриппа и его применение
KR102463632B1 (ko) 2014-07-10 2022-11-03 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 바이러스 백신 및 이의 용도
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
AU2016209032A1 (en) 2015-01-23 2017-08-10 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
KR20170133507A (ko) 2015-04-08 2017-12-05 다나-파버 캔서 인스티튜트 인크. 인간화된 인플루엔자 모노클로날 항체 및 그의 사용 방법
CA2985081A1 (en) 2015-05-13 2016-12-15 The Trustees Of The University Of Pennsylvania Aav-mediated expression of anti-influenza antibodies and methods of use thereof
EP3374390A1 (en) 2015-11-13 2018-09-19 Visterra, Inc. Compositions and methods for treating and preventing influenza
JP7237344B2 (ja) 2016-06-15 2023-03-13 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルス血球凝集素タンパク質及びその使用
CN106146657B (zh) * 2016-07-12 2020-07-17 晋明(天津)生物医药技术开发有限公司 广谱结合流感病毒a的重组抗体片段及其制备方法与应用
SG10201913833PA (en) 2017-02-28 2020-03-30 Univ Pennsylvania Influenza vaccines based on aav vectors
CA3053399A1 (en) 2017-02-28 2018-09-07 The Trustees Of The University Of Pennsylvania Novel adeno-associated virus (aav) clade f vector and uses therefor
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
CA3058652A1 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
EP3699186A4 (en) * 2017-10-18 2021-12-15 Xiamen University H3N2 INFLUENZA VIRUS MUTANT HEMAGGLUTININ MUTANT AND ITS USE
RS63526B1 (sr) 2018-01-23 2022-09-30 Janssen Vaccines & Prevention Bv Vakcine za virus gripa i njihove upotrebe
SG11202006379UA (en) 2018-01-26 2020-07-29 Regeneron Pharma Human antibodies to influenza hemagglutinin
US11230593B2 (en) 2019-03-25 2022-01-25 Visterra, Inc. Compositions and methods for treating and preventing influenza
US20230250135A1 (en) 2019-09-05 2023-08-10 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
US20220267382A1 (en) * 2019-09-20 2022-08-25 Academia Sinica Chimeric hemagglutinin protein and a vaccine composition comprising the same
CA3198897A1 (en) * 2019-12-13 2021-03-19 Autonomous Medical Devices Inc. Apparatus and method for point-of-care, rapid, field-deployable diagnostic testing of covid-19, viruses, antibodies and markers
WO2021173965A1 (en) 2020-02-28 2021-09-02 Massachusetts Institute Of Technology Identification of variable influenza residues and uses thereof
WO2021201677A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting influenza
JP2023551903A (ja) 2020-12-01 2023-12-13 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組織特異的標的化モチーフを有する新規組成物及びそれを含有する組成物
IL308404A (en) 2021-04-27 2024-01-01 Generation Bio Co Non-viral DNA vectors expressing therapeutic antibodies and uses thereof
WO2023177655A1 (en) 2022-03-14 2023-09-21 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
NL9101953A (nl) 1991-11-21 1993-06-16 Seed Capital Investments Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
ATE230850T1 (de) 1996-10-08 2003-01-15 Bisys B V U Verfahren und mittel zur auswahl von peptiden und proteinen mit spezifischer affinität zu einem zielmolekül
CN100457914C (zh) 1999-04-15 2009-02-04 荷兰克鲁塞尔公司 用编码腺病毒e1蛋白的序列在人体细胞中生产重组蛋白
AU2002345421B2 (en) 2001-06-15 2006-11-16 Crucell Holland B.V. Chimaeric phages
DE102004037820A1 (de) * 2004-08-04 2006-03-16 Epcos Ag Elektrische Schaltung und Bauelement mit der Schaltung
AU2006323315B2 (en) 2005-12-09 2014-02-20 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of antibody producing cells
EP2522678A1 (en) * 2006-05-15 2012-11-14 Sea Lane Biotechnologies, LLC Neutralizing antibodies to influenza viruses
US8148085B2 (en) 2006-05-15 2012-04-03 Sea Lane Biotechnologies, Llc Donor specific antibody libraries
US8192927B2 (en) * 2006-09-07 2012-06-05 Crucell Holland B.V. Human bind molecules capable of neutralizing influenza virus h5n1 and uses thereof
JP5305427B2 (ja) * 2007-01-11 2013-10-02 公立大学法人大阪府立大学 インフルエンザウイルスに対する抗体の産生方法
CN102046654A (zh) 2007-03-13 2011-05-04 胡马斯有限公司 针对甲型流感病毒h5n1株系的抗体
EP2201039B1 (en) * 2007-09-13 2015-07-15 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus h5-subtype or n1-subtype and uses thereof
FR2921928B1 (fr) * 2007-10-08 2011-03-04 Sanofi Pasteur Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal
AU2008338691B2 (en) * 2007-12-06 2015-01-22 Burnham Institute For Medical Research Antibodies against influenza virus and methods of use thereof
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
CA2761648C (en) * 2009-05-11 2019-03-12 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof

Also Published As

Publication number Publication date
KR101790354B9 (ko) 2017-10-25
AU2010247530B2 (en) 2016-10-13
CU23938B1 (es) 2013-08-29
CN102448986A (zh) 2012-05-09
CU20110206A7 (es) 2012-10-15
IL216222A (en) 2016-11-30
JP2012526526A (ja) 2012-11-01
CN102448986B (zh) 2015-11-25
EA029939B8 (ru) 2021-04-21
MY183517A (en) 2021-02-24
JP5813629B2 (ja) 2015-11-17
ES2934102T3 (es) 2023-02-16
BRPI1012749B1 (pt) 2022-01-11
US20120039898A1 (en) 2012-02-16
JP2016040261A (ja) 2016-03-24
TWI589300B (zh) 2017-07-01
US20130309248A1 (en) 2013-11-21
BRPI1012749A8 (pt) 2021-03-09
AU2010247530A1 (en) 2011-11-03
EA201171383A1 (ru) 2012-05-30
US20150175677A9 (en) 2015-06-25
US9611317B2 (en) 2017-04-04
WO2010130636A1 (en) 2010-11-18
EA029939B1 (ru) 2018-06-29
CA2761648A1 (en) 2010-11-18
KR20120034628A (ko) 2012-04-12
KR101790354B1 (ko) 2017-10-25
CN105418757A (zh) 2016-03-23
EP2430046A1 (en) 2012-03-21
IL216222A0 (en) 2012-01-31
US8470327B2 (en) 2013-06-25
EP2430046B1 (en) 2022-09-28
CN105418757B (zh) 2019-07-09
BRPI1012749A2 (pt) 2020-11-17
SG176003A1 (en) 2011-12-29
NZ596032A (en) 2013-09-27
TW201043248A (en) 2010-12-16
MX2011011331A (es) 2011-11-18
CA2761648C (en) 2019-03-12

Similar Documents

Publication Publication Date Title
AR076570A1 (es) Moleculas de union humanas capaces de neutralizar el virus de la influenza h3n2 y usos de las mismas
AR091316A1 (es) Moleculas de union humanas que se pueden unir y neutralizar a los virus de la influenza b y sus usos
AR084237A1 (es) Metodos para tratar virus de hepatitis c (hcv), composicion
CY1119896T1 (el) Μεθοδοι για αγωγη toy hcv
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
UY33897A (es) Inhibidores del virus de la hepatitis c
CL2016000805A1 (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
UY37581A (es) Compuestos para el tratamiento de la infección por virus de la hepatitis b
ECSP14013315A (es) Inhibidores de aplicación viral
CL2014003634A1 (es) Inhibidores del virus de la hepatitis c
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
EA201590703A1 (ru) Ингибиторы mek при лечении вирусных заболеваний
EA201500854A1 (ru) Композиция, содержащая по меньшей мере две связывающие молекулы, нейтрализующие вирус гриппа а
ECSP13012622A (es) Compuestos antivirales
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
EA201590709A1 (ru) Комбинированная терапия и ее применение для лечения димиелинизирующих расстройств
UY34066A (es) Inhibidores del virus de la hepatitis c
CR20160178A (es) Derivados de desoxinojirimicina y sus métodos de uso
UY32715A (es) Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados
BR112017004197A2 (pt) composições de vacina contra doenças do vírus da dengue
UY34420A (es) ?métodos de tratamiento del virus de la hepatitis c con que de gs-7977 y ribavirina, composiciones y usos"
BR112015001619A2 (pt) manosídeos multiméricos, um processo para a preparação dos mesmos e as suas utilizações como um medicamento
EA201790776A1 (ru) Комбинированные композиции длительного действия и способы лечения гепатита с
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c
TR201910305T4 (tr) Viral enfeksiyonları tedavi etmek için bileşikler.

Legal Events

Date Code Title Description
FC Refusal